Literature DB >> 7201845

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

D G Hirst, J M Brown, J L Hazlehurst.   

Abstract

Enhancement of CCNU cytotoxicity by misonidazole (MISO) was studied in three tumours and two normal tissues in the mouse. The 3 experimental tumours (SCCVII/St, EMT6 and KHT) showed very different sensitivities to CCNU alone, but MISO enhanced the cell killing in ech case. The effect was not always dose-modifying, so that the CCNU dose range for the greatest enhancement was different in each of the tumours. In all 3 tumours, enhancement increased with dose of MISO. The effect on two normal tissues, marrow (CFU-S) and testis (spermatogonia), was also investigated. Enhancement of marrow toxicity could be demonstrated only at CCNU doses greater than 12.5 mg/kg, so that at lower CCNU doses there was a therapeutic gain equal to the tumour enhancement ratio. The spermatogonia effect, however, showed enhancement by MISO similar to that seen in the tumours at all CCNU doses up to 20 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7201845      PMCID: PMC2011076          DOI: 10.1038/bjc.1982.172

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.

Authors:  J M Brown; N Y Yu; D M Brown; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-06       Impact factor: 7.038

3.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.

Authors:  R F Kallman; G Silini; L M Van Putten
Journal:  J Natl Cancer Inst       Date:  1967-09       Impact factor: 13.506

4.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

5.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.

Authors:  T C Stephens; V D Courtenay; J Mills; J H Peacock; C M Rose; D Spooner
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

7.  Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

8.  In vivo combination of misonidazole and the chemotherapeutic agent CCNU.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

9.  Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.

Authors:  M P Law; D G Hirst; J M Brown
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

10.  In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.

Authors:  R T Mulcahy; D W Siemann; R M Sutherland
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

View more
  29 in total

1.  Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.

Authors:  Han-Sin Jeong; Dennis Jones; Shan Liao; Daniel A Wattson; Cheryl H Cui; Dan G Duda; Christopher G Willett; Rakesh K Jain; Timothy P Padera
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

2.  Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.

Authors:  T Shibata; Y Shibamoto; K Sasai; N Oya; R Murata; T Takagi; M Hiraoka; M Takahashi; M Abe
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.

Authors:  Seong-Ho Kang; Bhumsuk Keam; Yong-Oon Ahn; Ha-Ram Park; Miso Kim; Tae Min Kim; Dong-Wan Kim; Dae Seog Heo
Journal:  Oncoimmunology       Date:  2018-09-21       Impact factor: 8.110

4.  Treatment of malignant gliomas in adults with BCNU plus metronidazole.

Authors:  D J Stewart; B Benoit; M T Richard; H Hugenholtz; J Dennery; N Russell; E Peterson; Z Grahovac; G Belanger; J A Maroun
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

5.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.

Authors:  Jason A Poff; Clint T Allen; Bryan Traughber; Aric Colunga; Jianwu Xie; Zhong Chen; Bradford J Wood; Carter Van Waes; King C P Li; Victor Frenkel
Journal:  Radiology       Date:  2008-06-23       Impact factor: 11.105

7.  Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.

Authors:  P J Wood; J M Sansom; I J Stratford; G E Adams; C Szabo; C Thiemermann; J R Vane
Journal:  Br J Cancer Suppl       Date:  1996-07

8.  Oncolytic activity of HF10 in head and neck squamous cell carcinomas.

Authors:  Shinichi Esaki; Fumi Goshima; Haruka Ozaki; Gaku Takano; Yoshimi Hatano; Daisuke Kawakita; Kei Ijichi; Takahiro Watanabe; Yoshitaka Sato; Takayuki Murata; Hiromitsu Iwata; Yuta Shibamoto; Shingo Murakami; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  Cancer Gene Ther       Date:  2019-09-03       Impact factor: 5.987

9.  Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner.

Authors:  M Barbosa de Souza Rizzo; M Brasilino de Carvalho; E J Kim; B E Rendon; J T Noe; A Darlene Wise; R A Mitchell
Journal:  QJM       Date:  2018-11-01

10.  Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

Authors:  J Wang; K A Biedermann; C R Wolf; J M Brown
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.